NCT07050368View on ClinicalTrials.gov

A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 28, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Healthy Volunteer
Interventions
DRUG

Psilocybin

Capsule containing active ingredient, psilocybin

DRUG

Placebo

Capsule with no active ingredients

Trial Locations (1)

NW10 7EW

RECRUITING

Hammersmith Medicines Research (HMR), London

Sponsors
All Listed Sponsors
lead

MycoMedica Life Sciences PBC

INDUSTRY